Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06239220 · ClinicalTrials.gov registry record · Phase 2

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Glenn J. Hanna.

Recruiting
Registry status
Phase 2
Development phase
25
Enrollment target
2
Study locations

NCT06239220 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Glenn J. Hanna. The registered enrollment target is 25 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06239220, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Glenn J. Hanna.

RECRUITING
Registry status
Phase 2
Development phase
25 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies involved in this study are: * PD-L1 t-haNK cell therapy (a NK cell therapy infusion) * NAI (a type of recombinant human superagonist) * Cetuximab (a type of antibody)

Conditions Studied

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Metastatic Head-and-neck Squamous-cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer

Interventions

  • DRUG Cetuximab
  • BIOLOGICAL PD-L1 t-haNK
  • BIOLOGICAL NAI

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2024-02-16
Est. Completion 2027-01-31
Phase Phase 2

Sponsor

Glenn J. Hanna

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06239220

The ClinicalTrials.gov registry entry for NCT06239220 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Glenn J. Hanna, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cetuximab is the first listed.

NCT06239220 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06239220 about?

NCT06239220 is a clinical study titled "PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC". The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies...

What is the current status of trial NCT06239220?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-02-16. Estimated completion is 2027-01-31.

What conditions does trial NCT06239220 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer.

What interventions are being tested in trial NCT06239220?

The interventions under investigation include: Cetuximab (DRUG), PD-L1 t-haNK (BIOLOGICAL), NAI (BIOLOGICAL).

Who is sponsoring clinical trial NCT06239220?

This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06239220 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.